UBI · ASX

Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (ASX:UBI)

AU$0.097

 0.001 (1.042%)
ASX:Live
15/01/2025 11:39:38 AM
Near Support Near 52 Week Low HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

UBI Overview

UBI Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About UBI

Website

Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh

Telephone

61.3.9213.9000

Address

1 Corporate Avenue Rowville, Victoria (VIC) 3178

Description

Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. Its products include blood glucose monitoring, coagulation testing, immunoassay, and molecular diagnostics. The company was founded in 2001 and is headquartered in Rowville, Australia.

UBI Price Chart

Key Stats

Market Cap

AU$28.61M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.1 - 0.28

Trade Value (12mth)

US$8,178.00

1 week

-4%

1 month

-23.2%

YTD

-3.03%

1 year

-54.81%

All time high

2.08

Key Fundamentals

EPS 3 yr Growth

-24.70%

EBITDA Margin

-236.90%

Operating Cashflow

-$10m

Free Cash Flow Return

-55.30%

ROIC

-25.50%

Interest Coverage

-88.60

Quick Ratio

3.00

Other Data

Shares on Issue (Fully Dilluted)

298m

HALO Sector

Healthcare

Next Company Report Date

21-Feb-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

UBI Announcements

Latest Announcements

Date Announcements

15 January 25

UBI Board Additions

×

UBI Board Additions

10 January 25

Notification of cessation of securities - UBI

×

Notification of cessation of securities - UBI

31 December 24

Appointment of Peter Mullin as Finance Director & CFO

×

Appointment of Peter Mullin as Finance Director & CFO

19 November 24

UBI signs NDC as its distribution partner for Xprecia Prime

×

UBI signs NDC as its distribution partner for Xprecia Prime

08 November 24

UBI signs Henry Schein as distribution partner for Xprecia

×

UBI signs Henry Schein as distribution partner for Xprecia

31 October 24

September 2024 Quarterly Activity Report and Appendix 4C

×

September 2024 Quarterly Activity Report and Appendix 4C

31 October 24

Q3 2024 Results

×

Q3 2024 Results

31 October 24

Q3 2024 Results Presentation

×

Q3 2024 Results Presentation

08 October 24

Notification regarding unquoted securities - UBI

×

Notification regarding unquoted securities - UBI

26 August 24

Xprecia Prime deal in India (Revised)

×

Xprecia Prime deal in India (Revised)

21 August 24

Italy Tender Win for Xprecia Prime

×

Italy Tender Win for Xprecia Prime

07 August 24

Universal Biosensors to host investor briefing and Q&A

×

Universal Biosensors to host investor briefing and Q&A

02 August 24

Appendix 4D and Half Year Results - 30 June 2024

×

Appendix 4D and Half Year Results - 30 June 2024

02 August 24

Half Year Results Presentation - 30 June 2024

×

Half Year Results Presentation - 30 June 2024

30 July 24

June 2024 Quarterly Activity Report and Appendix 4C

×

June 2024 Quarterly Activity Report and Appendix 4C

18 June 24

UBI receives $3.8m R&D Tax Incentive Rebate

×

UBI receives $3.8m R&D Tax Incentive Rebate

30 May 24

CEO's AGM address to Securityholders

×

CEO's AGM address to Securityholders

30 May 24

Results of 2024 Annual General Meeting

×

Results of 2024 Annual General Meeting

29 May 24

Acquisition of CDIs & Graham McLean App 3Y

×

Acquisition of CDIs & Graham McLean App 3Y

29 May 24

Change in substantial holding from HNG

×

Change in substantial holding from HNG

28 May 24

Appendix 3Y - Craig Coleman

×

Appendix 3Y - Craig Coleman

10 May 24

Appendix 3Y - Craig Coleman

×

Appendix 3Y - Craig Coleman

10 May 24

Change in substantial holding

×

Change in substantial holding

09 May 24

Appendix 3Y - Graham McLean

×

Appendix 3Y - Graham McLean

09 May 24

Appendix 3Y - Judith Smith

×

Appendix 3Y - Judith Smith

UBI Fundamentals

Per Share Records

Historical data

Forecast data

USD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.09 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.09 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -49.9 -111.3 76.2 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.04 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.05 -0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock -97.1 -14.1 55.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -6.0 -36.4 -40.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.11 0.08 0.06 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.06 0.08 0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -31.2 35.3 -24.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 188 210 212 Lock Lock Lock
Basic m Lock Lock Lock Lock 188 210 212 Lock Lock Lock

Financial Records

Historical data

Forecast data

USD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 4 3 4 Lock Lock Lock
     Growth % Lock Lock Lock Lock 96.8 -27.6 40.3 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 11 16 13 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 95.2 -564.1 722.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1.2 -11.3 50.1 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 101 111 50 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -9 -15 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -34.3 -56.3 28.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -215.9 -466.2 -236.9 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -11 -17 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30.6 -46.7 33.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -260.3 -527.7 -251.5 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -11 -24 -7 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -3 -5 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -8 -19 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -50.1 -136.2 76.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -181.9 -593.5 -101.6 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -7 -10 -10 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -1 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 17 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -8 -11 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -32.8 -42.3 5.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1.8 -3.6 -2.4 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 13 18 7 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 34 32 20 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 3 2 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -11 -15 -4 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 13 14 7 Lock Lock Lock
Equity $m Lock Lock Lock Lock 21 18 13 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 22 21 15 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.2 -5.1 -27.7 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -23.5 -58.1 -22.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -38.1 -102.9 -34.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -41.8 -78.6 -60.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -29.6 -90.4 -25.5 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -27.9 -49.5 -55.3 Lock Lock Lock

Ratios Records

Historical data

Forecast data

USD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -102.3 -97.0 -88.6 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.2 1.0 0.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -54.4 -83.1 -27.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 2.6 2.8 3.7 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.4 2.6 3.0 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 69.6 72.3 46.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -105.3 -112.4 -245.7 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 21.0 1.5 1.1 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 2.9 1.9 0.9 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.4 0.2 0.4 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 7.6 5.9 18.7 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.1 0.1 0.2 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.1 0.1 0.2 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -249.3 -766.0 -154.3 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -32.2 -75.0 -34.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -23.5 -58.1 -22.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.6 1.8 1.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -38.1 -102.9 -34.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -38.1 -102.9 -34.6 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 125.5 191.6 414.3 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 17.3 249.5 319.5 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 142.9 441.1 733.7 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 26.4 21.3 60.5 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 116.5 419.8 673.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

UBI Shortsell

Frequently Asked Questions

The current share price of Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) is AU$0.097.
The 52-week high share price for Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) is AU$0.28.
The 52-week low share price for Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX)? is AU$0.10.
Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) does not pay a dividend.
Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) does not pay a dividend.
Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) has a franking level of 0.0%.
Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) is classified in the Healthcare.
The current P/E ratio for Universal Biosensors, Inc. Shs Chess Depository Interests US Prohibited repr 1 sh (UBI:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.